“Updates on Colorectal Cancer” Webinar
Iranian Society of Radiation Oncology (ISRO) & Actero cooperated to hold a webinar, “Updates On Colorectal Cancer” on December 10th -2020, with the lectures of Dr. Mafi(Radio Oncologist), Dr. Yaghoubi Jouybari(Radio Oncologist) and Dr.Joudi(Radio Oncologists),followed by a discussion panel with presence of Dr.Taghizadeh (Radio Oncologist)& Dr. Motlagh(Radio Oncologist). At the beginning of mentioned webinar, we […]
Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.
Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib. Therefore, by delivering the drug sample to physicians specializing in this field, treatment […]
Breast Cancer Webinar
Simultaneously with the unveiling of Onkotaxel (Docetaxel of Actero Company), a subspecialized webinar was held on July 23rd with the presence of Dr. Safa Najafi (Medical Oncologist), Dr. Samiei (Radiotherapy Oncologist), Dr. Azimi Nejadan (Surgeon) and Ms. Dr. Ehsani (Pathologist) on August 2. The webinar discussed the latest updates in breast cancer diagnosis and treatment, […]
Production and launch of Favipiravir and Remdesivir in Actover Pharma group
With continuous monitoring of international research and protocols, it was suggested to produce drugs in the treatment of Covid-19 in the Actover group, as a pioneer in the production of drugs needed in Covid 19, the group unveiled two drugs, Remdesivir and Favipiravir. It should be noted that these two drugs have entered the official […]
Injection production line opening
After opening and operating the injection drug production line last year and increasing its production capacity in order to expand the product basket portfolio in the New Year, Actero factory, which specializes in the production of cancer drugs, intends to meet the needs of cancer patients in most treatment protocols. At present, Bortezomib, Pemetrexed , […]
Pharmex congress
The presence of Actover Pharmaceutical Group in the second Pharmex exhibition on June 30th to July 2nd at the Olympic Hotel as the main sponsor, as well as participation in scientific workshops.
COVID 19
Actero Company, considering its social responsibility and in order to meet the needs of Covid 19 disease aids, immediately imported the desired items and to some extent met the needs of the dear patients of the country. So far, more than 4,000 different PCR and antibody tests have been performed for Actover Group colleagues in […]
Multiple Myeloma and COVID 19 Webinar
Holding a subspecialty webinar on multiple myeloma management and COVID-19 on May 21st with the presence of prominent professors of medical oncology from Tehran, Dr. Mousavi, Dr. Razavi, Dr. Shahi, from Rasht, Dr. Najafi, from Isfahan, Dr. Ashrafi, simultaneously with the unveiling Bortezomib Acte was administered. This webinar talked about how to manage the treatment […]
ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE
Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg. Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal […]
WE ARE NOT JUST IMAGINING THE FUTURE – WE DO CREATE IT!
ACTERO pharmaceutical company is honored to announce the launch of its new scientific product in the field, The Journal of Current Oncology! As the first national English oncology journal, this eclectic review provides you cutting-edge findings in different scopes of clinical oncology collected from top ranking journals and well-known international oncology seminars in order to […]